BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health for Phase I/IIa Combination Study of Bria-IMT™

· Grant awarded to Dr. Saveri Bhattacharya, Principal Investigator of the Phase I/IIa combination study of Bria-IMT™ with KEYTRUDA® (by Merck) in advanced breast cancer at Thomas Jefferson University. · Merck to provide KEYTRUDA® for use in the combination study. · The Investigator Grant validates and will build on the encouraging preliminary data from BriaCell’s …

BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston

Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: • Bria-IMT™ in combination with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.); • Bria-IMT™ in combination with INCMGA00012 (by Incyte Corporation). BERKELEY, Calif., and VANCOUVER, British Columbia, January 28, 2020 — BriaCell …

BriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicine

BERKELEY, Calif., and VANCOUVER, British Columbia, January 22, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announced today that it will present at the “Frontiers in Academic Pathology” symposium, hosted by the Icahn School of Medicine at Mount Sinai, to …

BriaCell Provides Update on Remarkable Responder

• Patient initially identified September 19, 2019 as a Remarkable Responder; • Patient has continued to experience a highly remarkable reduction in tumors that had metastasized to areas outside of the breasts; • A metastasized tumor behind the left eye orbital region, which had pushed the eye forward from the skull, has now completely disappeared; …

BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade

• BriaCell has identified a patient population Biomarker with high rate of clinical benefit from the treatments based on ‘Breast Cancer Grade’; • Breast Cancer Grade correlates with response in both studies of monotherapy (Bria-IMT™ alone), and combination study of Bria-IMT™ with KEYTRUDA®; • New predicative Biomarker capability is complimentary to BriaCell’s HLA-matching hypothesis. BERKELEY, …

BriaCell Completes Share Consolidation

BERKELEY, Calif., and VANCOUVER, British Columbia, January 2, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has completed its previously announced consolidation of the common shares of the Company at a ratio of three …

BriaCell Therapeutics Corp. Announces Share Consolidation

BERKELEY, Calif., and VANCOUVER, British Columbia, December 24, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that its Board of Directors has approved a consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on …

BriaCell to Present at Biotech Showcase™ 2020 in San Francisco

BERKELEY, Calif., and VANCOUVER, British Columbia, December 17, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces its attendance and presentation scheduled at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the …

BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®

Safety and early efficacy data were presented on December 12th at 6:00 p.m. ET from the clinical trials of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: • Continued additive or synergistic activity observed in combination study of Bria-IMT™ with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.) as evident by tumor shrinkage …

BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th

Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: • Bria-IMT™ in combination with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.); • Bria-IMT™ in combination with INCMGA00012 (by Incyte Corporation). BERKELEY, Calif., and VANCOUVER, British Columbia, November 12, 2019 — BriaCell …